Navigation Links
Genelex Corporation Defends Consumers' Right to Obtain DNA Information:
Date:1/9/2008

Company founder urges government to apply rating system to home DNA tests

to protect against 'unscrupulous and misrepresented tests'

WASHINGTON, Jan. 9 /PRNewswire/ -- Should consumers have a right to obtain information regarding their personal health through home DNA tests? According to Genelex founder, Howard Coleman, the answer is: absolutely. "I agree with scientific opinion that tens of thousands of lives can be saved each year by DNA testing that reveal potential adverse drug reactions."

Coleman believes that such specific and accurate information will be the foundation for personalized medical treatment in the 21st century. "One pill does not fit all," Coleman states.

Genelex Corporation sells home DNA tests that analyze an individual's ability to process the most commonly prescribed and over the counter medication. "More than half the population has DNA alterations that can render many medications ineffective, or worse, trigger side effects that can prove to be fatal," Coleman said. Some common medications depend upon an individual's DNA for effectiveness and safety include Tamoxifen, Coumadin, Codeine and many others.

Coleman testified Tuesday before the President's Council of Advisors on Science and Technology in Washington DC (http://www.ostp.gov/PCAST/pcast.html). While Coleman supports consumers' access to home DNA tests, he shares some of the Council's concerns that there are unscrupulous companies that don't provide accurate or useful testing. Coleman suggested that companies who sell home DNA tests should, in cooperation with government agencies, implement a rating system that describes the certainty of their predictive value. "People have a fundamental right to learn and control this information. A rating system would allow people to decide if a particular test meets their needs."

Genelex Corporation was founded in 1987, and provides a program for comprehensive personalized medication management consisting of DNA testing and software for interpreting the test results based on all of the medicines a patient is taking.

For further information about Genelex go to http://www.Genelex.com. To contact Howard Coleman, call (206) 714-6393.


'/>"/>
SOURCE Genelex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
2. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
3. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
4. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
5. BioElectronics Corporation Announces Singapore and Malaysia Sales
6. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
7. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
8. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
9. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
10. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
11. Enova Medical Launches Exos Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):